Clinical trials: Children With Neurodevelopmental Disorders
Developmental and Epileptic Encephalopathy
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed…
- Trial name
- NCT06908226
- Testing
- LP352
- Where
- 88 sites in United States, Australia and 15 more
- Volunteers
- 324 people
- Sponsor
- Longboard Pharmaceuticals
Attention Deficit Hyperactivity Disorder
PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations
This is PART B of a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with ADHD with and without CNVs in specific genes implicated in glutamatergic signaling and…
- Trial name
- NCT03609619
- Testing
- AEVI-001
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Sleep Disorders, Neurodevelopmental Disorder
Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
The purpose of this study is to evaluate the efficacy on sleep latency with electronic sleep diaries and the safety of NPC-15.
- Trial name
- NPC-15-6 (NCT02757079)
- Testing
- NPC-15
- Volunteers
- 99 people
- Sponsor
- Nobelpharma
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Autism Spectrum Disorder
Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort
The purpose of this study is to evaluate the utility of and to clinically validate the Autism Behavior Inventory (ABI) in measuring clinical symptoms of Autism Spectrum Disorder (ASD) compared with other gold standard measures.
- Trial name
- NCT02668991
- Where
- 9 sites in United States
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Attention Deficit Hyperactivity Disorder
Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the long-term safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02704390
- Testing
- ORADUR®-Methylphenidate
- Where
- 3 sites in Taiwan
- Volunteers
- 64 people
- Sponsor
- Orient Pharma Co., Ltd.
Attention Deficit Hyperactivity Disorder
Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years
The objective of this study was to evaluate the plasma amphetamine concentration/time profile of amphetamine extended release oral suspension in children aged 4 to 5 years with attention-deficit/hyperactivity disorder, following…
- Trial name
- NCT03610464
- Testing
- Amphetamine Extended Release Suspension [Dyanavel]
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Autistic Disorder
A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
The objective of this study is to investigate the efficacy and safety of aripiprazole orally administered over a period of 8 weeks in pediatric patients with Autistic Disorder
- Trial name
- NCT01617447
- Testing
- Aripiprazole
- Where
- 5 sites in Japan
- Volunteers
- 92 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Rett Syndrome
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett Syndrome in adolescent and adult females.
- Trial name
- NCT01703533
- Testing
- NNZ-2566
- Where
- 3 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neuren Pharmaceuticals Limited
Autism
Deep rTMS (Repetitive Transcranial Magnetic Stimulation)for Treatment of Autism Symptoms in Children.
Autism is a developmental disorder characterized by abnormalities in speech and communication, impaired social functioning, and repetitive behaviors and interests.
- Trial name
- NCT01388179
- Testing
- Transcranial Magnetic Stimulation
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Brainsway
Dyslexia, Reading Disability
Brain Stimulation Paired With Structured Reading Instruction in Children With Dyslexia
This study investigates whether transcranial electrical stimulation (tES) delivered during structured reading instruction affects reading proficiency in children with developmental dyslexia and related reading disabilities.
- Trial name
- NCT07762365
- Testing
- Active transcranial electrical stimulation (tES)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- General Neuro Inc.
Autism
Safety and Efficacy of Stem Cell Therapy in Patients With Autism
Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by social interaction abnormalities, impaired verbal and non-verbal communication, and repetitive, obsessive behavior, while the therapeutic…
- Trial name
- NCT01343511
- Testing
- human cord blood mononuclear cells, human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Attention Deficit Hyperactivity Disorder
Concordance of the Quotient Attention Deficit Hyperactivity Disorder (ADHD) System Report With Teacher and Parent Assessments for Symptoms of ADHD
To demonstrate concordance between the Quotient ADHD System Report and standard DSM-IV based parent and teacher reported rating/assessment scales, currently the accepted method of symptom measurement for subjects diagnosed with…
- Trial name
- NCT01118650
- Sponsor
- BioBehavioral Diagnostics Company
Drug Resistant Epilepsy, Autism Spectrum Disorder
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD.
- Conditions
- Drug Resistant Epilepsy, Autism Spectrum Disorder, Chronic Migraine, Brain Tumor, Pediatric
- Trial name
- NCT06309251
- Testing
- ketogenic diet (as per clinical practice)
- Where
- 3 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Danone Nutricia SpA Società Benefit
Attention Deficit-Hyperactivity Disorder
Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) in Attention-Deficit/Hyperactivity Disorder
The main objective of the study is to demonstrate the non-inferiority of the personalized Neurofeedback Training device versus Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity…
- Trial name
- Newrofeed (NCT02778360)
- Testing
- Neurofeedback NFT, Methylphenidate MPH
- Where
- 12 sites in Belgium, France and 3 more
- Volunteers
- 179 people
- Sponsor
- Mensia Technologies SA
Attention-Deficit/Hyperactivity Disorder
Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for children with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00640419
- Testing
- ABT-089
- Where
- 13 sites in United States
- Volunteers
- 121 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Attention Deficit Hyperactivity Disorder (ADHD)
The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD
ADHD is the most frequent neurodevelopmental disorder in childhood. Symptoms often appear in preschool years, and most children (65-80%) continue to experience some ADHD-associated symptoms into adolescence and adulthood.
- Trial name
- NCT06542445
- Testing
- Oral CBD oil enriched with terpenes
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Bazelet Nehushtan LtD.
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191516
- Testing
- Atomoxetine
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
- Trial name
- NCT03325881
- Testing
- SHP465
- Where
- 41 sites in United States
- Volunteers
- 89 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to gain initial safety, tolerability, pharmacokinetic, and efficacy information on SPD489 in preschool children 4-5 years old who are diagnosed with ADHD.
- Trial name
- NCT02402166
- Testing
- SPD489
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire